Welcome to our dedicated page for TEVJF SEC filings (Ticker: TEVJF), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on TEVJF's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into TEVJF's regulatory disclosures and financial reporting.
Form 144 notice for TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVJF): The filer notifies a proposed sale of 95,000 American Depositary Shares through Piper Sandler & Co. (Greenwich, CT) with an approximate aggregate market value of $1,889,550.00. The securities outstanding figure listed is 1,147,150,917. The proposed approximate sale date is 09/12/2025. The shares were acquired on 05/09/2018 and the date of payment is recorded as 05/09/2018. The filing reports "Nothing to Report" for securities sold in the past three months and includes the required representation that the seller does not possess undisclosed material adverse information about the issuer.
